keyword
MENU ▼
Read by QxMD icon Read
search

Multiple sclerosis drugs

keyword
https://www.readbyqxmd.com/read/29045030/drug-delivery-to-the-brain-across-the-blood-brain-barrier-using-nanomaterials
#1
REVIEW
Yung-Hao Tsou, Xue-Qing Zhang, He Zhu, Sahla Syed, Xiaoyang Xu
A major obstacle facing brain diseases such as Alzheimer's disease, multiple sclerosis, brain tumors, and strokes is the blood-brain barrier (BBB). The BBB prevents the passage of certain molecules and pathogens from the circulatory system into the brain. Therefore, it is nearly impossible for therapeutic drugs to target the diseased cells without the assistance of carriers. Nanotechnology is an area of growing public interest; nanocarriers, such as polymer-based, lipid-based, and inorganic-based nanoparticles can be engineered in different sizes, shapes, and surface charges, and they can be modified with functional groups to enhance their penetration and targeting capabilities...
October 16, 2017: Small
https://www.readbyqxmd.com/read/29042375/non-invasive-brain-stimulation-interventions-for-management-of-chronic-central-neuropathic-pain-a-scoping-review-protocol
#2
Mei Lin Chen, Lin Yao, Jennifer Boger, Kathryn Mercer, Benjamin Thompson, Ning Jiang
INTRODUCTION: Pain can affect people regardless of age, gender or ethnicity. Chronic central neuropathic pain (CCNP) is a debilitating condition that affects populations such as stroke survivors, amputees, spinal cord injury patients and patients with multiple sclerosis, with prevalence rates between 30% and 80%. This condition can be caused by a lesion or disease affecting the somatosensory system. CCNP is notoriously drug resistant, and few effective CCNP treatment or management strategies exist...
October 16, 2017: BMJ Open
https://www.readbyqxmd.com/read/29041872/progressive-ms-trials-lessons-learned
#3
Carmen Tur, Xavier Montalban
Up to very recently, no treatments had proved effective in progressive multiple sclerosis (MS). In 2016, four drugs, two tested in phase 3 and two in phase 2 trials, showed a beneficial effect in primary or secondary progressive MS. Although this could indicate a turning point in progressive MS treatment, most of these successes have been modest and mainly restricted to patients with active inflammation, in the context of trials with powerful anti-inflammatory agents. This paper summarises these reasons, particularly focusing on the main lessons learned for the design of future trials...
October 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29041866/-progressive-ms-macro-views-the-need-for-novel-clinical-trial-paradigms-to-enable-drug-development-for-progressive-ms
#4
P Zaratin, G Comi, D Leppert
This article outlines the principal challenges to establish a standard phase-2 approach for progressive multiple sclerosis (PMS) and presents referring strategies to accelerate the registration process via a guidance approved by regulatory agencies. Accordingly, the contribution of 'big datasets' for a better understanding of the natural history of primary-progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) and of their prognostic factors and the value of novel biomarkers are discussed...
October 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29038005/prednisone-alleviates-demyelination-through-regulation-of-the-nlrp3-inflammasome-in-a-c57bl-6-mouse-model-of-cuprizone-induced-demyelination
#5
Hao Yu, Mingfeng Wu, Geng Lu, Tingting Cao, Nan Chen, Yijia Zhang, Higuo Jiang, Hongbin Fan, Ruiqin Yao
Myelin abnormalities, oligodendrocyte damage, and concomitant glia activation are common in demyelinating diseases of the central nervous system (CNS). Increasing evidence has demonstrated that the inflammatory response triggers demyelination and gliosis in demyelinating disorders. Numerous clinical interventions, including those used to treat multiple sclerosis (MS), have confirmed prednisone (PDN) as a powerful anti-inflammatory drug that reduces the inflammatory response and promotes tissue repair in multiple inflammation sites...
October 13, 2017: Brain Research
https://www.readbyqxmd.com/read/29034884/generation-of-six-multiple-sclerosis-patient-derived-induced-pluripotent-stem-cell-lines
#6
L Miquel-Serra, A Duarri, Y Muñoz, B Kuebler, B Aran, C Costa, M Martí, M Comabella, S Malhotra, X Montalban, A Veiga, A Raya
Multiple sclerosis (MS) is considered a chronic autoimmune disease of the central nervous system that leads to gliosis, demyelination, axonal damage and neuronal death. The MS disease aetiology is unknown, though a polymorphism of the TNFRSF1A gene, rs1800693, is known to confer an increased risk for MS. Using retroviral delivery of reprogramming transgenes, we generated six MS patient-specific iPSC lines with two distinct genotypes, CC or TT, of the polymorphism rs1800693. iPSC lines had normal karyotype, expressed pluripotency genes and differentiated into the three germ layers...
October 2017: Stem Cell Research
https://www.readbyqxmd.com/read/29034533/efficacy-tolerability-and-safety-of-cannabis-based-medicines-for-chronic-pain-management-an-overview-of-systematic-reviews
#7
REVIEW
W Häuser, F Petzke, M-A Fitzcharles
Medicinal cannabis has already entered mainstream medicine in some countries. This systematic review (SR) aimed at evaluating the efficacy, acceptability and safety of cannabis-based medicines for chronic pain management. Qualitative systematic review of SRs of randomized controlled trials with cannabis-based medicines for chronic pain management. The Cochrane databases of SRs, Database of Abstracts of Reviews of Effects and PubMed were searched for SR published in the period January 2009 to January 2017. Assessment of the methodological quality of SR was performed by the AMSTAR checklist...
October 15, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/29033895/autoimmune-thyroid-diseases-in-patients-treated-with-alemtuzumab-for-multiple-sclerosis-an-example-of-selective-anti-tsh-receptor-immune-response
#8
REVIEW
Mario Rotondi, Martina Molteni, Paola Leporati, Valentina Capelli, Michele Marinò, Luca Chiovato
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of active relapsing-remitting multiple sclerosis (MS). Alemtuzumab induces a rapid and prolonged depletion of lymphocytes from the circulation, which results in a profound immuno-suppression status followed by an immune reconstitution phase. Secondary to reconstitution autoimmune diseases represent the most common side effect of Alemtuzumab treatment. Among them, Graves' disease (GD) is the most frequent one with an estimated prevalence ranging from 16...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29031194/the-prevalence-and-characteristics-of-epilepsy-in-patients-with-multiple-sclerosis-in-nordland-county-norway
#9
Espen Benjaminsen, Kjell-Morten Myhr, Karl B Alstadhaug
PURPOSE: The prevalence of epilepsy among patients with multiple sclerosis (MS) has been found higher than in the general population. Although cortical pathology may be involved, the causal link between MS and epileptic seizures is still unclear. We aimed to identify and describe the patients with active epilepsy in a previously described population based MS-cohort. METHODS: Medical records of all patients with MS in Nordland County on January 1, 2010, were scrutinizing for evidence of comorbid seizures and epilepsy...
October 6, 2017: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/29029896/clemastine-fumarate-as-a-remyelinating-therapy-for-multiple-sclerosis-rebuild-a-randomised-controlled-double-blind-crossover-trial
#10
Ari J Green, Jeffrey M Gelfand, Bruce A Cree, Carolyn Bevan, W John Boscardin, Feng Mei, Justin Inman, Sam Arnow, Michael Devereux, Aya Abounasr, Hiroko Nobuta, Alyssa Zhu, Matt Friessen, Roy Gerona, Hans Christian von Büdingen, Roland G Henry, Stephen L Hauser, Jonah R Chan
BACKGROUND: Multiple sclerosis is a degenerative inflammatory disease of the CNS characterised by immune-mediated destruction of myelin and progressive neuroaxonal loss. Myelin in the CNS is a specialised extension of the oligodendrocyte plasma membrane and clemastine fumarate can stimulate differentiation of oligodendrocyte precursor cells in vitro, in animal models, and in human cells. We aimed to analyse the efficacy and safety of clemastine fumarate as a treatment for patients with multiple sclerosis...
October 10, 2017: Lancet
https://www.readbyqxmd.com/read/29029375/treatment-and-disease-management-of-multiple-sclerosis-patients-a-review-for-nurse-practitioners
#11
Cortnee Roman, Kara Menning
BACKGROUND AND PURPOSE: This review discusses the role of the nurse practitioner (NP) in evaluating the clinical effects, potential side effects, and monitoring requirements for treatment options in multiple sclerosis (MS) and provides guidance on how to help patients understand these issues. METHODS: A literature search was conducted on PubMed to identify publications on monitoring and disease management of MS patients. Additional resources included drug information web sites and package inserts...
October 2017: Journal of the American Association of Nurse Practitioners
https://www.readbyqxmd.com/read/28991670/follow-on-products-for-treatment-of-multiple-sclerosis-in-latin-america-an-update
#12
REVIEW
Jorge Correale
Both proprietary and non-proprietary medicines are expected to undergo rigorous pre-approval testing and both should meet stringent health authority regulatory requirements related to quality to obtain approval. Non-proprietary (also known as copy or generic) medicines, which base their authorization and use on the proprietary documentation and label, are often viewed as a means to help lower cost and thus increase patient access. If these medicines fail to meet quality standards, such as good manufacturing practice and bioequivalence (in humans), they are then defined as substandard copies and can pose serious risks to patients in terms of safety and efficacy...
October 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28990513/protective-effects-of-the-caffeine-against-neurodegenerative-diseases
#13
Ester Tellone, Antonio Galtieri, Annamaria Russo, Silvana Ficarra
Caffeine is one of the most consumed stimulant of the central nervous system. Similar to those of other stimulants, its effects are to improve brain activity and stimulate cognition learning and memory. Caffeine affects the brain by acting mainly as a non-selective blocker of the adenosine receptors (A1, A2A, A2B, and A3). The purpose of this review article is to provide an overview on the neurobiochemical impact of caffeine, focusing on the ability of the drug to effectively counteract several neurodegenerative disorders such as Alzheimer's, Parkinson's, Huntington's diseases, Multiple sclerosis and Amyotrophic lateral sclerosis and Epilepsy...
October 9, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28990207/a-review-of-bioanalytical-quantitative-methods-for-selected-sphingosine-1-phosphate-s1p1-receptor-modulators
#14
REVIEW
Ranjeet Prasad Dash, Nuggehally R Srinivas, Rana Rais
Sphingosine 1-phosphate (S1P1 ) modulators provide an emerging therapeutic approach for various autoimmune disorders such as multiple sclerosis and psoriasis. Fingolimod is the first approved orally active, selective and potent drug of this class. Other drugs belonging to this class include siponimod, ponesimod, ceralifimod, amiselimod, CS-0777 and GSK2018682. However, due to the high protein binding, polarity and zwitter-ionic nature of the phosphate metabolite of parent drugs, it becomes challenging to optimize the extraction method for this class of compounds...
October 9, 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/28989795/a-comparison-of-multiple-sclerosis-disease-activity-after-discontinuation-of-fingolimod-and-placebo
#15
Patrick Vermersch, Ernst-Wilhelm Radue, Norman Putzki, Shannon Ritter, Martin Merschhemke, Mark S Freedman
BACKGROUND: Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation. OBJECTIVE: The objective of this paper is to assess the risk of substantially higher-than-expected disease activity post-study drug discontinuation (SDD) at the individual patient level using data from the Phase III, placebo-controlled FREEDOMS and FREEDOMS II trials. METHODS: Baseline gadolinium-enhancing T1-lesion volumes were used to statistically model the expected level of MRI disease activity post-SDD...
July 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/28984619/the-therapeutic-use-of-non-invasive-brain-stimulation-in-multiple-sclerosis-a-review
#16
Rosa Iodice, Fiore Manganelli, Raffaele Dubbioso
BACKGROUND: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and a leading cause of disability in young adults. Many disabling symptoms in MS, such as spasticity, pain, depression and cognitive deficits are not fully controlled by drug treatment. Non-invasive brain stimulation (NIBS) techniques can be used as tools for modulating altered cortical excitability and plasticity MS patients, providing an improvement in disabling symptoms affecting such patients...
2017: Restorative Neurology and Neuroscience
https://www.readbyqxmd.com/read/28982479/nurse-led-immunotreatment-decision-coaching-in-people-with-multiple-sclerosis-decims-feasibility-testing-pilot-randomised-controlled-trial-and-mixed-methods-process-evaluation
#17
A C Rahn, S Köpke, I Backhus, J Kasper, K Anger, B Untiedt, A Alegiani, I Kleiter, I Mühlhauser, C Heesen
BACKGROUND: Treatment decision-making is complex for people with multiple sclerosis. Profound information on available options is virtually not possible in regular neurologist encounters. The "nurse decision coach model" was developed to redistribute health professionals' tasks in supporting immunotreatment decision-making following the principles of informed shared decision-making. OBJECTIVES: To test the feasibility of a decision coaching programme and recruitment strategies to inform the main trial...
August 26, 2017: International Journal of Nursing Studies
https://www.readbyqxmd.com/read/28980606/-modern-conception-of-the-pathogenesis-of-neurodegenerative-diseases-and-therapeutic-strategy
#18
I V Litvinenko, I V Krasakov, G N Bisaga, D I Skulyabin, I D Poltavsky
Here we discuss the pathogenesis of the inflammatory and degenerative nervous system disorders on the example of Parkinson's disease, Alzheimer's disease, multiple sclerosis. Common mechanisms of neurodegeneration in these diseases are reviewed. The role of neurodegeneration as the main process leading to the resistant disability of patients with multiple sclerosis is discussed. The authors consider a contribution of inflammatory process and chronic infection to the manifestation and progressing of a neurodegenerative disease and discuss the use of treatment not usually indicated including interferon, anti-inflammatory drugs, statin, vitamin D, monoclonal antibodies, correction of the intestinal microbiota in Parkinson's disease and Alzheimer's disease...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28979825/it-s-time-for-combination-therapies-in-multiple-sclerosis
#19
EDITORIAL
Jagannadha Avasarala
The treatment of multiple sclerosis continues to evolve. However, even with the introduction of B-cell depleting monoclonal antibodies, disability progression continues unabated since B-cell therapies are unable to cross the blood brain barrier and thus are unable to address the disease that lurks within the brain. In this commentary, the author explores the research and practice of using B-cell depleting monoclonal antibody therapies in MS. The author provides discussion on the blood brain barrier as the primary limitation to the effectiveness of MS therapies...
May 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28979794/disease-modifying-therapies-in-multiple-sclerosis-in-latin-america
#20
REVIEW
Eli Skromne-Eisenberg, Laura Ordoñez-Boschetti, Irene Treviño-Frenk
The treatment of multiple sclerosis (MS) has become increasingly complex during the last 10 years, mainly because of the advent of new and more potent disease-modifying therapies (DMTs). In Latin America, the therapeutic repertoire available for MS treatment is similar to the one in the rest of the world, but the high costs of these drugs, in conjunction with the limited resources of the social security health systems, makes the treatment of MS more difficult. For neurologists in Latin America, providing personalized MS treatment has become a challenge...
July 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
keyword
keyword
18958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"